Cybrdi is a holding company incorporated with 80% equity in Chaoying Biotech, which is engaged in biotechnology manufacturing, and research and development.. Through Chaoying Biotech, Cybrdi also controls SD Chaoying, a cultural and entertainment company with a special license for casino gambling.
Biotechnology Manufacturing, R&D Business
Chaoying Biotech is actively seeking to expand its biotechnology manufacturing business. Tissue chips, also called micro-tissue arrays, represent a newly developed technology which is intended to provide high-throughput molecular profiling and parallel analysis of biological and molecular characteristics for hundreds of pathologically controlled tissue specimens. Tissue arrays can, at times, provide rapid and cost-effective localization and evaluation of proteins, RNA, or DNA molecules, which is particularly useful for functioning genomic studies. Cybrdi manufactures both human and animal tissue micro-array for a wide variety of scientific uses, including drug discovery and development.
We supply Biomax Ltd., a United States research and development subcontractor for Pfizer, and, through Biomax we provide our products and services to other major biotechnology companies in the U.S.and Europe such as America Nanoarray. We are also a supplier for the China’s National Biomedical Center, Shanghai Biochip Center, a research partner with Peking University Academy of Military Medical Sciences, and perform dermatological research and development for Lancome and Estee Lauder. Starting in 2010, our sole domestic sales representative in China will be Xi’an AiLiNa Biotechnology Co., Ltd,, and the only overseas sales representative will be Biomax. We will mainly distribute our products through these two sales representatives.
We are the patent holder and producer of Tissue Microarrays (TMAs) which are a powerful tool to examine disease pathology across a variety of patients and disease conditions. We also hold three patents in antibody detection.
Our manufacturing facility and a pathology and molecule laboratory is located at an approximately18,000 square foot facility that we own in Shaanxi province. At this facility, we have established the standard tissue chip production, processing procedure and a quality control system. We have also established an electronic management system to effectively manage biologic information databank.
Culture, Entertainment, and Real Estate Business
Chaoying Biotech owns 83.33% of SD Chaoying, a culture and entertainment company with a special license for casino gambling. SD Chaoying is developing a Culture and Entertainment Square in Changle City of Shangdong Province on the 33,333 square meter land it owns the right to use. The usage areas of the Square will be approximately 19,145 square meters. With the entertainment facilities of restaurants spas, hotel rooms, movie theaters, cosmetic and personal care salons, body buildup gyms, the Square will become local cultural and entertainment center. The facility construction project annexed with four multi-family residential buildings (about 14,188 square meters), and two of them had been completed and some of the housing units had been sold. The total cost for the construction is estimated to be $8.2 million. At present, SD Chaoying has invested approximately $4.8 million in the construction. The proceeds of the sales of the residential units will be applied to the casino and resort construction.. The special permit for the casino business we acquired from Shandong Administration for Civil Affairs will provide us an advantage for attracting people from surrounding areas. We believe that the potential for a cultural and entertainment business is enhanced as living standards rise in the region. We anticipate financing the balance of the construction in part from the sale of the residential buildings, which will be completed first. However, there is no assurance regarding the proceeds that will be generated from the sale of the residential units. We believe that the balance of any funding will need to be obtained from affiliated companies or from banks.
Reverse Merger Filing
